Migraine treatment with external concurrent occipital and trigeminal neurostimulation—A randomized controlled trial
Objective To evaluate the efficacy and safety of concurrent non‐invasive stimulation of occipital and trigeminal nerves in acute treatment of migraine with or without aura. Background Non‐invasive neuromodulation devices stimulating a single peripheral nerve or anatomic distribution are routinely us...
Uložené v:
| Vydané v: | Headache Ročník 62; číslo 8; s. 989 - 1001 |
|---|---|
| Hlavní autori: | , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
Mt. Royal
Wiley Subscription Services, Inc
01.09.2022
|
| Predmet: | |
| ISSN: | 0017-8748, 1526-4610, 1526-4610 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Objective
To evaluate the efficacy and safety of concurrent non‐invasive stimulation of occipital and trigeminal nerves in acute treatment of migraine with or without aura.
Background
Non‐invasive neuromodulation devices stimulating a single peripheral nerve or anatomic distribution are routinely used by patients with migraine refractory to the first‐line drugs or those who opt out of pharmaceutical treatment. Concurrent occipital and trigeminal stimulation was described in an invasive setting, and its safety cost outweighed its efficacy gain. This study evaluated the efficacy and safety of an external concurrent occipital and trigeminal device in acute treatment of migraine.
Design and Methods
This was a randomized, sham‐controlled, double‐blind, multi‐center trial. Patients 18 years of age or older who met the International Classification of Headache Disorders (2018) diagnostic criteria for migraine with or without aura, reported 1–6 migraine attacks per month, and other headaches no more than 6 days per month were enrolled. Of 131 intention‐to‐treat participants (67 and 64 in the active and sham groups, respectively), 109 (50 and 59 in the active and sham groups, respectively) treated at least one migraine episode. Reduction of migraine headache (pain relief) 2 h after treatment initiation was the primary efficacy endpoint. Pain relief at 1 h, and pain freedom and relief in most bothersome symptom at 2 h after treatment initiation were the secondary endpoints. Freedom from most bothersome symptom at 2 h and sustained pain freedom 24 h after treatment initiation were among the exploratory endpoints.
Results
Sixty percent of participants (30/50) in the active arm reported pain relief at 2 h after initiation of the first eligible treatment (primary outcome) compared to 37% (22/59) in the control arm (difference, 23%; 95% confidence interval [CI], 2%–41%; p = 0.018). Pain freedom at 2 h without rescue medication was reported by 46% (23/50) of participants in the active arm and by 12% (7/59) of participants in the sham arm (p < 0.001). Pain freedom 2 h after the treatment and, subsequently, at 24 h, was reported by 4.25 times more participants in the active arm (36%; 18/50) than in the sham arm (8%; 5/59). The 28% difference was statistically significant (95% CI, 1%–43%; p < 0.001). A 4.25‐fold difference was also observed comparing the proportion of participants free from pain and most bothersome symptom 2 h after the stimulation (47% [17/36] and 11% [5/45] in the active and sham arms, respectively; 95% CI, 14%–54%; p < 0.001). Adverse events were not serious or severe. All study‐related events resolved without treatment.
Conclusion
External concurrent occipital and trigeminal neurostimulation is a well‐tolerated, safe, and effective migraine treatment that provided a fast and durable relief and freedom from migraine pain and associated symptoms in a randomized setting. The observed safety and performance suggest external concurrent occipital and trigeminal neurostimulation is a viable alternative to the currently available acute migraine treatments.
Trial registration
clinicaltrials.gov identifier NCT03631550. |
|---|---|
| AbstractList | To evaluate the efficacy and safety of concurrent non-invasive stimulation of occipital and trigeminal nerves in acute treatment of migraine with or without aura.OBJECTIVETo evaluate the efficacy and safety of concurrent non-invasive stimulation of occipital and trigeminal nerves in acute treatment of migraine with or without aura.Non-invasive neuromodulation devices stimulating a single peripheral nerve or anatomic distribution are routinely used by patients with migraine refractory to the first-line drugs or those who opt out of pharmaceutical treatment. Concurrent occipital and trigeminal stimulation was described in an invasive setting, and its safety cost outweighed its efficacy gain. This study evaluated the efficacy and safety of an external concurrent occipital and trigeminal device in acute treatment of migraine.BACKGROUNDNon-invasive neuromodulation devices stimulating a single peripheral nerve or anatomic distribution are routinely used by patients with migraine refractory to the first-line drugs or those who opt out of pharmaceutical treatment. Concurrent occipital and trigeminal stimulation was described in an invasive setting, and its safety cost outweighed its efficacy gain. This study evaluated the efficacy and safety of an external concurrent occipital and trigeminal device in acute treatment of migraine.This was a randomized, sham-controlled, double-blind, multi-center trial. Patients 18 years of age or older who met the International Classification of Headache Disorders (2018) diagnostic criteria for migraine with or without aura, reported 1-6 migraine attacks per month, and other headaches no more than 6 days per month were enrolled. Of 131 intention-to-treat participants (67 and 64 in the active and sham groups, respectively), 109 (50 and 59 in the active and sham groups, respectively) treated at least one migraine episode. Reduction of migraine headache (pain relief) 2 h after treatment initiation was the primary efficacy endpoint. Pain relief at 1 h, and pain freedom and relief in most bothersome symptom at 2 h after treatment initiation were the secondary endpoints. Freedom from most bothersome symptom at 2 h and sustained pain freedom 24 h after treatment initiation were among the exploratory endpoints.DESIGN AND METHODSThis was a randomized, sham-controlled, double-blind, multi-center trial. Patients 18 years of age or older who met the International Classification of Headache Disorders (2018) diagnostic criteria for migraine with or without aura, reported 1-6 migraine attacks per month, and other headaches no more than 6 days per month were enrolled. Of 131 intention-to-treat participants (67 and 64 in the active and sham groups, respectively), 109 (50 and 59 in the active and sham groups, respectively) treated at least one migraine episode. Reduction of migraine headache (pain relief) 2 h after treatment initiation was the primary efficacy endpoint. Pain relief at 1 h, and pain freedom and relief in most bothersome symptom at 2 h after treatment initiation were the secondary endpoints. Freedom from most bothersome symptom at 2 h and sustained pain freedom 24 h after treatment initiation were among the exploratory endpoints.Sixty percent of participants (30/50) in the active arm reported pain relief at 2 h after initiation of the first eligible treatment (primary outcome) compared to 37% (22/59) in the control arm (difference, 23%; 95% confidence interval [CI], 2%-41%; p = 0.018). Pain freedom at 2 h without rescue medication was reported by 46% (23/50) of participants in the active arm and by 12% (7/59) of participants in the sham arm (p < 0.001). Pain freedom 2 h after the treatment and, subsequently, at 24 h, was reported by 4.25 times more participants in the active arm (36%; 18/50) than in the sham arm (8%; 5/59). The 28% difference was statistically significant (95% CI, 1%-43%; p < 0.001). A 4.25-fold difference was also observed comparing the proportion of participants free from pain and most bothersome symptom 2 h after the stimulation (47% [17/36] and 11% [5/45] in the active and sham arms, respectively; 95% CI, 14%-54%; p < 0.001). Adverse events were not serious or severe. All study-related events resolved without treatment.RESULTSSixty percent of participants (30/50) in the active arm reported pain relief at 2 h after initiation of the first eligible treatment (primary outcome) compared to 37% (22/59) in the control arm (difference, 23%; 95% confidence interval [CI], 2%-41%; p = 0.018). Pain freedom at 2 h without rescue medication was reported by 46% (23/50) of participants in the active arm and by 12% (7/59) of participants in the sham arm (p < 0.001). Pain freedom 2 h after the treatment and, subsequently, at 24 h, was reported by 4.25 times more participants in the active arm (36%; 18/50) than in the sham arm (8%; 5/59). The 28% difference was statistically significant (95% CI, 1%-43%; p < 0.001). A 4.25-fold difference was also observed comparing the proportion of participants free from pain and most bothersome symptom 2 h after the stimulation (47% [17/36] and 11% [5/45] in the active and sham arms, respectively; 95% CI, 14%-54%; p < 0.001). Adverse events were not serious or severe. All study-related events resolved without treatment.External concurrent occipital and trigeminal neurostimulation is a well-tolerated, safe, and effective migraine treatment that provided a fast and durable relief and freedom from migraine pain and associated symptoms in a randomized setting. The observed safety and performance suggest external concurrent occipital and trigeminal neurostimulation is a viable alternative to the currently available acute migraine treatments.CONCLUSIONExternal concurrent occipital and trigeminal neurostimulation is a well-tolerated, safe, and effective migraine treatment that provided a fast and durable relief and freedom from migraine pain and associated symptoms in a randomized setting. The observed safety and performance suggest external concurrent occipital and trigeminal neurostimulation is a viable alternative to the currently available acute migraine treatments.clinicaltrials.gov identifier NCT03631550.TRIAL REGISTRATIONclinicaltrials.gov identifier NCT03631550. ObjectiveTo evaluate the efficacy and safety of concurrent non‐invasive stimulation of occipital and trigeminal nerves in acute treatment of migraine with or without aura.BackgroundNon‐invasive neuromodulation devices stimulating a single peripheral nerve or anatomic distribution are routinely used by patients with migraine refractory to the first‐line drugs or those who opt out of pharmaceutical treatment. Concurrent occipital and trigeminal stimulation was described in an invasive setting, and its safety cost outweighed its efficacy gain. This study evaluated the efficacy and safety of an external concurrent occipital and trigeminal device in acute treatment of migraine.Design and MethodsThis was a randomized, sham‐controlled, double‐blind, multi‐center trial. Patients 18 years of age or older who met the International Classification of Headache Disorders (2018) diagnostic criteria for migraine with or without aura, reported 1–6 migraine attacks per month, and other headaches no more than 6 days per month were enrolled. Of 131 intention‐to‐treat participants (67 and 64 in the active and sham groups, respectively), 109 (50 and 59 in the active and sham groups, respectively) treated at least one migraine episode. Reduction of migraine headache (pain relief) 2 h after treatment initiation was the primary efficacy endpoint. Pain relief at 1 h, and pain freedom and relief in most bothersome symptom at 2 h after treatment initiation were the secondary endpoints. Freedom from most bothersome symptom at 2 h and sustained pain freedom 24 h after treatment initiation were among the exploratory endpoints.ResultsSixty percent of participants (30/50) in the active arm reported pain relief at 2 h after initiation of the first eligible treatment (primary outcome) compared to 37% (22/59) in the control arm (difference, 23%; 95% confidence interval [CI], 2%–41%; p = 0.018). Pain freedom at 2 h without rescue medication was reported by 46% (23/50) of participants in the active arm and by 12% (7/59) of participants in the sham arm (p < 0.001). Pain freedom 2 h after the treatment and, subsequently, at 24 h, was reported by 4.25 times more participants in the active arm (36%; 18/50) than in the sham arm (8%; 5/59). The 28% difference was statistically significant (95% CI, 1%–43%; p < 0.001). A 4.25‐fold difference was also observed comparing the proportion of participants free from pain and most bothersome symptom 2 h after the stimulation (47% [17/36] and 11% [5/45] in the active and sham arms, respectively; 95% CI, 14%–54%; p < 0.001). Adverse events were not serious or severe. All study‐related events resolved without treatment.ConclusionExternal concurrent occipital and trigeminal neurostimulation is a well‐tolerated, safe, and effective migraine treatment that provided a fast and durable relief and freedom from migraine pain and associated symptoms in a randomized setting. The observed safety and performance suggest external concurrent occipital and trigeminal neurostimulation is a viable alternative to the currently available acute migraine treatments.Trial registrationclinicaltrials.gov identifier NCT03631550. Objective To evaluate the efficacy and safety of concurrent non‐invasive stimulation of occipital and trigeminal nerves in acute treatment of migraine with or without aura. Background Non‐invasive neuromodulation devices stimulating a single peripheral nerve or anatomic distribution are routinely used by patients with migraine refractory to the first‐line drugs or those who opt out of pharmaceutical treatment. Concurrent occipital and trigeminal stimulation was described in an invasive setting, and its safety cost outweighed its efficacy gain. This study evaluated the efficacy and safety of an external concurrent occipital and trigeminal device in acute treatment of migraine. Design and Methods This was a randomized, sham‐controlled, double‐blind, multi‐center trial. Patients 18 years of age or older who met the International Classification of Headache Disorders (2018) diagnostic criteria for migraine with or without aura, reported 1–6 migraine attacks per month, and other headaches no more than 6 days per month were enrolled. Of 131 intention‐to‐treat participants (67 and 64 in the active and sham groups, respectively), 109 (50 and 59 in the active and sham groups, respectively) treated at least one migraine episode. Reduction of migraine headache (pain relief) 2 h after treatment initiation was the primary efficacy endpoint. Pain relief at 1 h, and pain freedom and relief in most bothersome symptom at 2 h after treatment initiation were the secondary endpoints. Freedom from most bothersome symptom at 2 h and sustained pain freedom 24 h after treatment initiation were among the exploratory endpoints. Results Sixty percent of participants (30/50) in the active arm reported pain relief at 2 h after initiation of the first eligible treatment (primary outcome) compared to 37% (22/59) in the control arm (difference, 23%; 95% confidence interval [CI], 2%–41%; p = 0.018). Pain freedom at 2 h without rescue medication was reported by 46% (23/50) of participants in the active arm and by 12% (7/59) of participants in the sham arm (p < 0.001). Pain freedom 2 h after the treatment and, subsequently, at 24 h, was reported by 4.25 times more participants in the active arm (36%; 18/50) than in the sham arm (8%; 5/59). The 28% difference was statistically significant (95% CI, 1%–43%; p < 0.001). A 4.25‐fold difference was also observed comparing the proportion of participants free from pain and most bothersome symptom 2 h after the stimulation (47% [17/36] and 11% [5/45] in the active and sham arms, respectively; 95% CI, 14%–54%; p < 0.001). Adverse events were not serious or severe. All study‐related events resolved without treatment. Conclusion External concurrent occipital and trigeminal neurostimulation is a well‐tolerated, safe, and effective migraine treatment that provided a fast and durable relief and freedom from migraine pain and associated symptoms in a randomized setting. The observed safety and performance suggest external concurrent occipital and trigeminal neurostimulation is a viable alternative to the currently available acute migraine treatments. Trial registration clinicaltrials.gov identifier NCT03631550. |
| Author | Kuruvilla, Deena E. Deutsch, Lisa Grosberg, Brian Daniel, Oved Vainstein, Gabriel Tepper, Stewart J. Sharon, Roni |
| Author_xml | – sequence: 1 givenname: Stewart J. surname: Tepper fullname: Tepper, Stewart J. email: sjtepper@gmail.com organization: Dartmouth Headache Center – sequence: 2 givenname: Brian surname: Grosberg fullname: Grosberg, Brian organization: University of Connecticut School of Medicine – sequence: 3 givenname: Oved surname: Daniel fullname: Daniel, Oved organization: Ramat‐Aviv Medical Center – sequence: 4 givenname: Deena E. surname: Kuruvilla fullname: Kuruvilla, Deena E. organization: Westport Headache Institute – sequence: 5 givenname: Gabriel surname: Vainstein fullname: Vainstein, Gabriel organization: Maccabi Healthcare Services – sequence: 6 givenname: Lisa surname: Deutsch fullname: Deutsch, Lisa organization: BioStats Statistical Consulting Ltd – sequence: 7 givenname: Roni orcidid: 0000-0002-2452-8921 surname: Sharon fullname: Sharon, Roni organization: Chaim Sheba (Tel HaShomer) Medical Center |
| BookMark | eNp9kc1KxDAUhYOM4Piz8QkKbkSo5m866XIYR0cYcaPrkqa3miFNxjTFn5UP4RP6JKbW1SDeTeDmOwfuOftoZJ0FhI4JPidxLp5AVueEswneQWMyoVnKM4JHaIwxmaZiysUe2m_bNcaYZ3k2Rt2tfvRSW0iCBxkasCF50eEpgdcA3kqTKGdV533_4ZTSGx3iUtoqCvQjNLpnLHTetUE3nZFBO_v18TlLfIRco9-h6j2Cd8bAj0qaQ7RbS9PC0e97gB6uFvfzZbq6u76Zz1apYozjNBeApQKheMUUq3IxUVjSMmecVFSWjNIKGCgFqpTltKaizpkEwXDFaE5Lwg7Q6eC78e65gzYUjW4VGCMtuK4taCYIZlTwHj3ZQteu6wOI1JRwynHGaaTOBkrFe1sPdbHxupH-rSC46Bso-gaKnwYijLdgFcPr8wkxcvO3hAySF23g7R_zYrmYXQ6abyfQnug |
| CitedBy_id | crossref_primary_10_1007_s40120_023_00529_x crossref_primary_10_1055_a_2116_8022 crossref_primary_10_1111_nmo_14899 crossref_primary_10_1177_25158163251377996 crossref_primary_10_3389_fneur_2023_1263535 crossref_primary_10_7326_ANNALS_24_00551 crossref_primary_10_1097_01_JAA_0000000000000014 crossref_primary_10_1111_head_14860 crossref_primary_10_1111_head_14671 crossref_primary_10_1212_CON_0000000000001402 crossref_primary_10_1212_WNL_0000000000207677 crossref_primary_10_1007_s00415_023_11706_1 crossref_primary_10_12677_tcm_2024_1310395 |
| Cites_doi | 10.1016/S1474-4422(18)30499-X 10.1111/ane.13050 10.1111/ner.12267 10.1111/head.14067 10.1007/s00415-017-8404-4 10.1016/S0140-6736(16)31678-6 10.1016/S1474-4422(18)30322-3 10.1007/s10072-020-04643-8 10.1212/WNL.0000000000005857 10.1016/S0140-6736(15)60692-4 10.1111/head.12601 10.1152/physrev.00034.2015 10.1186/s10194-020-01110-9 10.1212/WNL.0b013e3182825055 10.1186/s10194-018-0928-1 10.1212/CPJ.0000000000000848 10.1007/s12325-020-01494-9 10.1111/head.13708 10.3171/2013.6.FOCUS13233 10.1177/0333102419828967 10.1111/head.12110 10.1111/head.13551 10.1056/NEJMct0910887 10.1186/s10194-019-1033-9 10.1186/s10194-016-0693-y 10.1001/jama.284.20.2599 10.1212/WNL.0000000000002918 10.1080/17434440.2021.1908122 10.1111/head.12111 10.1016/S1474-4422(17)30299-5 10.1177/0333102418811573 10.1212/WNL.0000000000003327 10.1177/0333102413508661 10.1111/j.1468-2982.2009.01996.x 10.1111/head.14153 10.1007/s40120-020-00196-2 10.1212/01.wnl.0000252808.97649.21 10.1186/s10194-018-0929-0 |
| ContentType | Journal Article |
| Copyright | 2022 American Headache Society. 2022 American Headache Society |
| Copyright_xml | – notice: 2022 American Headache Society. – notice: 2022 American Headache Society |
| DBID | AAYXX CITATION 7TK 7U7 C1K K9. 7X8 |
| DOI | 10.1111/head.14350 |
| DatabaseName | CrossRef Neurosciences Abstracts Toxicology Abstracts Environmental Sciences and Pollution Management ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
| DatabaseTitle | CrossRef ProQuest Health & Medical Complete (Alumni) Toxicology Abstracts Neurosciences Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic ProQuest Health & Medical Complete (Alumni) |
| Database_xml | – sequence: 1 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1526-4610 |
| EndPage | 1001 |
| ExternalDocumentID | 10_1111_head_14350 HEAD14350 |
| Genre | miscellaneous |
| GrantInformation_xml | – fundername: Neurolief Ltd |
| GroupedDBID | --- .3N .GA .GJ .Y3 05W 0R~ 10A 1OB 1OC 29I 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5HH 5LA 5RE 5VS 66C 6PF 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANHP AANLZ AAONW AAQQT AASGY AAWTL AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABIVO ABJNI ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFNX AFFPM AFGKR AFPWT AFRAH AFWVQ AFZJQ AHBTC AHMBA AI. AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBS ECV EJD EMOBN ESX EX3 F00 F01 F04 F5P FEDTE FUBAC FYBCS G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO L7B LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ TEORI UB1 VH1 W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQ9 WQJ WRC WVDHM WXI WXSBR XG1 YCJ YFH YUY ZGI ZXP ZZTAW ~IA ~WT AAMMB AAYXX AEFGJ AEYWJ AGHNM AGQPQ AGXDD AGYGG AIDQK AIDYY AIQQE CITATION O8X 7TK 7U7 C1K K9. 7X8 |
| ID | FETCH-LOGICAL-c3340-98e0ace8c4d3c3d985c0a2b9341d2ab322de3eccecbab7f28f93ae830d3292b13 |
| IEDL.DBID | DRFUL |
| ISICitedReferencesCount | 12 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000815136200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0017-8748 1526-4610 |
| IngestDate | Wed Oct 01 14:46:53 EDT 2025 Mon Oct 06 16:55:43 EDT 2025 Sat Nov 29 06:56:55 EST 2025 Tue Nov 18 21:51:03 EST 2025 Wed Jan 22 16:24:18 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 8 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3340-98e0ace8c4d3c3d985c0a2b9341d2ab322de3eccecbab7f28f93ae830d3292b13 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| ORCID | 0000-0002-2452-8921 |
| PQID | 2714240642 |
| PQPubID | 24968 |
| PageCount | 13 |
| ParticipantIDs | proquest_miscellaneous_2681032841 proquest_journals_2714240642 crossref_primary_10_1111_head_14350 crossref_citationtrail_10_1111_head_14350 wiley_primary_10_1111_head_14350_HEAD14350 |
| PublicationCentury | 2000 |
| PublicationDate | September 2022 2022-09-00 20220901 |
| PublicationDateYYYYMMDD | 2022-09-01 |
| PublicationDate_xml | – month: 09 year: 2022 text: September 2022 |
| PublicationDecade | 2020 |
| PublicationPlace | Mt. Royal |
| PublicationPlace_xml | – name: Mt. Royal |
| PublicationTitle | Headache |
| PublicationYear | 2022 |
| Publisher | Wiley Subscription Services, Inc |
| Publisher_xml | – name: Wiley Subscription Services, Inc |
| References | 2015; 18 2020; 41 2020; 60 2015; 386 2019; 59 2015; 55 2016; 388 2010; 363 2019; 39 2020; 37 2019; 18 2016; 17 2018; 19 2017; 97 2018; 17 2021; 11 2019; 20 2013; 35 2021 2017; 16 2020 2021; 18 2013; 53 2020; 9 2013; 80 2016; 87 2018; 91 2018 2000; 284 2019; 139 2020; 21 2017; 264 2021; 61 2007; 68 2014; 34 2010; 30 e_1_2_11_10_1 e_1_2_11_31_1 e_1_2_11_30_1 e_1_2_11_14_1 e_1_2_11_13_1 e_1_2_11_35_1 e_1_2_11_12_1 e_1_2_11_34_1 e_1_2_11_11_1 e_1_2_11_7_1 e_1_2_11_29_1 e_1_2_11_6_1 e_1_2_11_28_1 (e_1_2_11_32_1) 2021 e_1_2_11_5_1 e_1_2_11_27_1 e_1_2_11_4_1 e_1_2_11_26_1 e_1_2_11_3_1 e_1_2_11_2_1 (e_1_2_11_36_1) 2020 e_1_2_11_21_1 e_1_2_11_20_1 (e_1_2_11_33_1) 2018 e_1_2_11_25_1 e_1_2_11_40_1 e_1_2_11_24_1 e_1_2_11_41_1 e_1_2_11_9_1 e_1_2_11_23_1 e_1_2_11_42_1 e_1_2_11_8_1 e_1_2_11_22_1 e_1_2_11_18_1 e_1_2_11_17_1 e_1_2_11_16_1 e_1_2_11_15_1 e_1_2_11_37_1 e_1_2_11_38_1 e_1_2_11_39_1 e_1_2_11_19_1 |
| References_xml | – volume: 17 start-page: 100 year: 2016 article-title: Thalamo‐cortical network activity between migraine attacks: Insights from MRI‐based microstructural and functional resting‐state network correlation analysis publication-title: J Headache Pain – volume: 18 start-page: 459 year: 2019 end-page: 480 article-title: Global, regional, and national burden of neurological disorders, 1990‐2016: a systematic analysis for the Global Burden of Disease Study 2016 publication-title: Lancet Neurol. – volume: 21 start-page: 41 year: 2020 article-title: A global real‐world assessment of the impact on health‐related quality of life and work productivity of migraine in patients with insufficient versus good response to triptan medication publication-title: J Headache Pain – volume: 35 year: 2013 article-title: Dual occipital and supraorbital nerve stimulation for chronic migraine: a single‐center experience, review of literature, and surgical considerations publication-title: Neurosurg Focus. – volume: 9 start-page: 535 year: 2020 end-page: 549 article-title: The humanistic and economic burden of migraine in Europe: a cross‐sectional survey in five countries publication-title: Neurol Ther – volume: 41 start-page: 429 year: 2020 end-page: 436 article-title: Gender‐related differences in migraine publication-title: Neurol Sci – volume: 87 start-page: 2154 year: 2016 end-page: 2160 article-title: Thalamo‐cortical network activity during spontaneous migraine attacks publication-title: Neurology – volume: 17 start-page: 954 year: 2018 end-page: 976 article-title: Global, regional, and national burden of migraine and tension‐type headache, 1990‐2016: a systematic analysis for the Global Burden of Disease Study 2016 publication-title: Lancet Neurol – year: 2021 – volume: 388 start-page: 1545 year: 2016 end-page: 1602 article-title: Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990‐2015: a systematic analysis for the Global Burden of Disease Study 2015 publication-title: Lancet – volume: 20 start-page: 83 year: 2019 article-title: Remote electrical neuromodulation (REN) in the acute treatment of migraine: a comparison with usual care and acute migraine medications publication-title: J Headache Pain. – volume: 97 start-page: 553 year: 2017 end-page: 622 article-title: Pathophysiology of migraine: a disorder of sensory processing publication-title: Physiol Rev – volume: 53 start-page: 17 issue: Suppl 1 year: 2013 end-page: 20 article-title: Oral triptans and nausea: treatment considerations in migraine publication-title: Headache – volume: 284 start-page: 2599 year: 2000 end-page: 2605 article-title: Disability in Strategies of Care Study g. Stratified care vs step care strategies for migraine: the Disability in Strategies of Care (DISC) Study: a randomized trial publication-title: JAMA – volume: 60 start-page: 416 year: 2020 end-page: 429 article-title: Most bothersome symptom in persons with migraine: results from the Migraine in America Symptoms and Treatment (MAST) study publication-title: Headache – volume: 18 start-page: 333 year: 2021 end-page: 342 article-title: A device review of Relivion(R): an external combined occipital and trigeminal neurostimulation (eCOT‐NS) system for self‐administered treatment of migraine and major depressive disorder publication-title: Expert Rev Med Devices – volume: 61 start-page: 263 year: 2021 end-page: 275 article-title: Systematic review of outcomes and endpoints in acute migraine clinical trials publication-title: Headache – volume: 87 start-page: 529 year: 2016 end-page: 538 article-title: Chronic migraine headache prevention with noninvasive vagus nerve stimulation: the EVENT study publication-title: Neurology – year: 2018 – volume: 37 start-page: 4765 year: 2020 end-page: 4796 article-title: Evaluation of patients with insufficient efficacy and/or tolerability to triptans for the acute treatment of migraine: a systematic literature review publication-title: Adv Ther – volume: 363 start-page: 63 year: 2010 end-page: 70 article-title: Triptan therapy in migraine publication-title: N Engl J Med – volume: 11 start-page: e344 year: 2021 end-page: e346 article-title: Sumatriptan anaphylaxis: a headache of an allergy publication-title: Neurol Clin Pract – volume: 59 start-page: 1240 year: 2019 end-page: 1252 article-title: Remote electrical neuromodulation (REN) relieves acute migraine: a randomized, double‐blind, placebo‐controlled, multicenter trial publication-title: Headache – volume: 386 start-page: 743 year: 2015 end-page: 800 article-title: Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990‐2013: a systematic analysis for the Global Burden of Disease Study 2013 publication-title: Lancet – volume: 19 start-page: 101 year: 2018 article-title: Consistent effects of non‐invasive vagus nerve stimulation (nVNS) for the acute treatment of migraine: additional findings from the randomized, sham‐controlled, double‐blind PRESTO trial publication-title: J Headache Pain – volume: 264 start-page: 654 year: 2017 end-page: 663 article-title: The sensorimotor network dysfunction in migraineurs without aura: a resting‐state fMRI study publication-title: J Neurol – volume: 91 start-page: e364 year: 2018 end-page: e373 article-title: Noninvasive vagus nerve stimulation as acute therapy for migraine: the randomized PRESTO study publication-title: Neurology – volume: 16 start-page: 877 year: 2017 end-page: 897 article-title: Global, regional, and national burden of neurological disorders during 1990‐2015: a systematic analysis for the Global Burden of Disease Study 2015 publication-title: Lancet Neurol – volume: 55 start-page: 221 issue: Suppl 4 year: 2015 end-page: 235 article-title: Triptans in the Acute Treatment of Migraine: a Systematic Review and Network Meta‐Analysis publication-title: Headache – volume: 80 start-page: 697 year: 2013 end-page: 704 article-title: Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial publication-title: Neurology – volume: 139 start-page: 276 year: 2019 end-page: 283 article-title: Combination of flunarizine and transcutaneous supraorbital neurostimulation improves migraine prophylaxis publication-title: Acta Neurol Scand – volume: 39 start-page: 3 year: 2019 end-page: 14 article-title: Acute migraine therapy with external trigeminal neurostimulation (ACME): a randomized controlled trial publication-title: Cephalalgia – volume: 39 start-page: 687 year: 2019 end-page: 710 article-title: Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: fourth edition publication-title: Cephalalgia – volume: 19 start-page: 98 year: 2018 article-title: Practical and clinical utility of non‐invasive vagus nerve stimulation (nVNS) for the acute treatment of migraine: a post hoc analysis of the randomized, sham‐controlled, double‐blind PRESTO trial publication-title: J Headache Pain – year: 2020 – volume: 53 start-page: 11 issue: Suppl 1 year: 2013 end-page: 16 article-title: Why triptan treatment can fail: focus on gastrointestinal manifestations of migraine publication-title: Headache – volume: 68 start-page: 343 year: 2007 end-page: 349 article-title: Migraine prevalence, disease burden, and the need for preventive therapy publication-title: Neurology – volume: 61 start-page: 1021 year: 2021 end-page: 1039 article-title: The American Headache Society Consensus Statement: update on integrating new migraine treatments into clinical practice publication-title: Headache – volume: 30 start-page: 260 year: 2010 end-page: 271 article-title: Combined occipital and supraorbital neurostimulation for the treatment of chronic migraine headaches: initial experience publication-title: Cephalalgia – volume: 18 start-page: 297 year: 2015 end-page: 303 article-title: Concordant occipital and supraorbital neurostimulation therapy for hemiplegic migraine; initial experience; a case series publication-title: Neuromodulation – volume: 34 start-page: 258 year: 2014 end-page: 267 article-title: Comparative efficacy of triptans for the abortive treatment of migraine: a multiple treatment comparison meta‐analysis publication-title: Cephalalgia – ident: e_1_2_11_8_1 doi: 10.1016/S1474-4422(18)30499-X – ident: e_1_2_11_20_1 doi: 10.1111/ane.13050 – ident: e_1_2_11_42_1 doi: 10.1111/ner.12267 – ident: e_1_2_11_35_1 doi: 10.1111/head.14067 – ident: e_1_2_11_39_1 doi: 10.1007/s00415-017-8404-4 – ident: e_1_2_11_3_1 doi: 10.1016/S0140-6736(16)31678-6 – ident: e_1_2_11_5_1 doi: 10.1016/S1474-4422(18)30322-3 – ident: e_1_2_11_4_1 doi: 10.1007/s10072-020-04643-8 – ident: e_1_2_11_25_1 doi: 10.1212/WNL.0000000000005857 – ident: e_1_2_11_9_1 doi: 10.1016/S0140-6736(15)60692-4 – ident: e_1_2_11_38_1 doi: 10.1111/head.12601 – ident: e_1_2_11_10_1 doi: 10.1152/physrev.00034.2015 – volume-title: Migraine: Developing Drugs for Acute Treatment year: 2018 ident: e_1_2_11_33_1 – ident: e_1_2_11_18_1 doi: 10.1186/s10194-020-01110-9 – ident: e_1_2_11_21_1 doi: 10.1212/WNL.0b013e3182825055 – ident: e_1_2_11_26_1 doi: 10.1186/s10194-018-0928-1 – ident: e_1_2_11_17_1 doi: 10.1212/CPJ.0000000000000848 – ident: e_1_2_11_15_1 doi: 10.1007/s12325-020-01494-9 – ident: e_1_2_11_12_1 doi: 10.1111/head.13708 – ident: e_1_2_11_29_1 doi: 10.3171/2013.6.FOCUS13233 – ident: e_1_2_11_34_1 doi: 10.1177/0333102419828967 – ident: e_1_2_11_13_1 doi: 10.1111/head.12110 – ident: e_1_2_11_22_1 doi: 10.1111/head.13551 – ident: e_1_2_11_16_1 doi: 10.1056/NEJMct0910887 – ident: e_1_2_11_23_1 doi: 10.1186/s10194-019-1033-9 – ident: e_1_2_11_40_1 doi: 10.1186/s10194-016-0693-y – ident: e_1_2_11_37_1 doi: 10.1001/jama.284.20.2599 – ident: e_1_2_11_24_1 doi: 10.1212/WNL.0000000000002918 – ident: e_1_2_11_31_1 doi: 10.1080/17434440.2021.1908122 – ident: e_1_2_11_14_1 doi: 10.1111/head.12111 – ident: e_1_2_11_2_1 doi: 10.1016/S1474-4422(17)30299-5 – ident: e_1_2_11_19_1 doi: 10.1177/0333102418811573 – volume-title: Statistical Considerations for Clinical Trials During the COVID‐19 Public Health Emergency year: 2020 ident: e_1_2_11_36_1 – ident: e_1_2_11_41_1 doi: 10.1212/WNL.0000000000003327 – volume-title: Relivion K203419 year: 2021 ident: e_1_2_11_32_1 – ident: e_1_2_11_11_1 doi: 10.1177/0333102413508661 – ident: e_1_2_11_30_1 doi: 10.1111/j.1468-2982.2009.01996.x – ident: e_1_2_11_28_1 doi: 10.1111/head.14153 – ident: e_1_2_11_7_1 doi: 10.1007/s40120-020-00196-2 – ident: e_1_2_11_6_1 doi: 10.1212/01.wnl.0000252808.97649.21 – ident: e_1_2_11_27_1 doi: 10.1186/s10194-018-0929-0 |
| SSID | ssj0004696 |
| Score | 2.4312792 |
| Snippet | Objective
To evaluate the efficacy and safety of concurrent non‐invasive stimulation of occipital and trigeminal nerves in acute treatment of migraine with or... ObjectiveTo evaluate the efficacy and safety of concurrent non‐invasive stimulation of occipital and trigeminal nerves in acute treatment of migraine with or... To evaluate the efficacy and safety of concurrent non-invasive stimulation of occipital and trigeminal nerves in acute treatment of migraine with or without... |
| SourceID | proquest crossref wiley |
| SourceType | Aggregation Database Enrichment Source Index Database Publisher |
| StartPage | 989 |
| SubjectTerms | Effectiveness Headache Migraine Neuromodulation neurostimulation occipital nerve Pain Patients Peripheral nerves Safety Signs and symptoms Statistical analysis Stimulation trigeminal nerve |
| Title | Migraine treatment with external concurrent occipital and trigeminal neurostimulation—A randomized controlled trial |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fhead.14350 https://www.proquest.com/docview/2714240642 https://www.proquest.com/docview/2681032841 |
| Volume | 62 |
| WOSCitedRecordID | wos000815136200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library - Journals customDbUrl: eissn: 1526-4610 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0004696 issn: 0017-8748 databaseCode: DRFUL dateStart: 19970101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LaxsxEB7SpJRekvQR4rxQaC8tbFlL60gLuZjYJofYlFKDb4teaxbsdYjtHnrqj8gvzC-JRqu1XQiBkNvCjthF0jw-aWY-gK_WNFvacBuJXMUOoDR1pDhNIi7TVuJQUIub3JNN8MFAjEbpzy24rGthqv4QqwM31Axvr1HBpZpvKDly2P9Ab-8A-w5WVTnotdP51RvebNRFen6uyhLzRIT2pJjJsx79v0NaR5mbsap3Nr291_3mPuyGIJO0q13xAbZs-RHe9cM1-idY9osxUkNYssozJ3ggS-qe0MShZF11biIzrQtPLUJkadyAYmw9ERipWmEuimlgAHv4d98mzvWZ2bT4aw0JWfAT60fJyWcY9rq_r66jwL8QacaSOEqFjaW2QieGaWZS0dKxpCp1js9QqZwpMJa5LWC1kornVOQpk1aw2DCaUtVkB7Bdzkp7COQCYZFKcmdARKKsFCrF2Ig5sGhozk0DvtWLkOnQnBw5MiZZDVJwHjM_jw34spK9rVpyPCl1Uq9lFtRynlGOhX2IuRpwvnrtFApvSWRpZ0sngx3amPPazQZ89yv7zFey626745-OXiJ8DO8pllH4XLUT2F7cLe0pvNV_FsX87gze8JE4C5v5EWZu-o0 |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bSxtBFD6UKNqXeqdpbZ2iLworm5mNM_sYjCFiEooo-LbMbcNC3IgmPvjkj-gv7C_pnNnJRShC6dvCnmGXmTm3mXO-D-DImkZTG24jkavYJSgNHSlOk4jLtJm4LKjJTe7JJvhgIO7u0p-hNgd7YSp8iPmBG2qGt9eo4HggvaTlSGJ_iu7eZewryRnjogYr7evObW-pMdITdFWmmCci4JNiKc9i9FuPtAgzl4NV7206G__5n5vwKYSZpFXtiy34YMttWOuHi_QdmPaLIZJDWDKvNCd4JEtmqNDE5cm6wm4iY60LTy5CZGncgGJoPRUYqcAwJ8V94AD7_fqrRZzzM-P74sUaEurgR9aPkqNduO1c3Jx3o8DAEGnGkjhKhY2ltkInhmlmUtHUsaQqda7PUKmcMTCWuU1gtZKK51TkKZNWsNgwmlLVYHtQK8el_QzkDBMjleTOhIhEWSlUitERc-mioTk3dTierUKmAzw5smSMslmagvOY-Xmsw-Fc9qEC5fir1P5sMbOgmE8Z5djah1lXHX7MXzuVwnsSWdrx1MkgRhtzfrtRhxO_tO98JetetNr-6cu_CB_Aevem38t6l4Orr_CRYlOFr1zbh9rkcWq_wap-nhRPj9_Dnv4Dcqf9lQ |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bS9xAFD6UtYgv9qLitrYdqS8KkexM0pk8Ll0Xi7pIqeBbmMuJBNas6G4f-uSP8Bf2l3TOZHbdghSkb4GcSUJmzuWbOed8AHvoerl1EhNVmdQDlJ5NjORZInWRZx4F5dJVgWxCjkbq8rI4j7k5VAvT9odYbLiRZgR7TQqON65a0nIisT8kd-8R-0qW-2d3YGXwfXhxulQYGQi6WlMsMxX7k1Iqz-Povz3SY5i5HKwGbzN89Z_f-RrWY5jJ-u26eAMvsHkLq2fxIH0DZmf1FZFDIFtkmjPakmXzrtDM42Tb9m5iE2vrQC7CdOP8gPoKAxUYa5thTuvryAH2-_6hz7zzc5Pr-hc6FvPgxxhG6fEmXAyPfnw9TiIDQ2KFyNKkUJhqi8pmTljhCpXbVHNTeNfnuDbeGDgUfhGgNdrIiquqEBqVSJ3gBTc9sQWdZtLgNrAvBIxMVnkTojKDWpmCoiPh4aLjlXRd2J_PQmlje3JiyRiXc5hC_7EM_7ELnxeyN21TjielduaTWUbFvCu5pNI-Ql1d2F3c9ipF5yS6wcnMy1CPNuH9dq8LB2Fq__GW8vioPwhX754j_AlWzwfD8vTb6OQ9rHGqqQiJazvQmd7O8AO8tD-n9d3tx7ik_wAC6_0Q |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Migraine+treatment+with+external+concurrent+occipital+and+trigeminal+neurostimulation-A+randomized+controlled+trial&rft.jtitle=Headache&rft.au=Tepper%2C+Stewart+J&rft.au=Grosberg%2C+Brian&rft.au=Daniel%2C+Oved&rft.au=Kuruvilla%2C+Deena+E&rft.date=2022-09-01&rft.issn=1526-4610&rft.eissn=1526-4610&rft.volume=62&rft.issue=8&rft.spage=989&rft_id=info:doi/10.1111%2Fhead.14350&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0017-8748&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0017-8748&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0017-8748&client=summon |